Clostridium difficile Infection in Patients with Ulcerative Colitis Treated with Tofacitinib in the Ulcerative Colitis Program
暂无分享,去创建一个
E. Loftus | A. Armuzzi | D. Baumgart | C. Su | K. Kwok | L. Salese | J. Woolcott | K. Gecse | J. Kinnucan | S. Connelly
[1] A. Hart,et al. Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open‐label, long‐term extension study with up to 7.0 years of treatment , 2021, Alimentary pharmacology & therapeutics.
[2] C. Le Berre,et al. Newer Biologic and Small-Molecule Therapies for Inflammatory Bowel Disease. , 2021, The New England journal of medicine.
[3] M. Toruner,et al. ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease. , 2021, Journal of Crohn's & colitis.
[4] D. Rubin,et al. Long-Duration Oral Vancomycin to Treat Clostridioides difficile in Patients With Inflammatory Bowel Disease Is Associated With a Low Rate of Recurrence. , 2019, The American journal of gastroenterology.
[5] Ashwin N. Ananthakrishnan,et al. ACG Clinical Guideline: Ulcerative Colitis in Adults , 2019, The American journal of gastroenterology.
[6] P. Gaburri,et al. Impact of superimposed Clostridium difficile infection in Crohn’s or ulcerative colitis flares in the outpatient setting , 2018, International Journal of Colorectal Disease.
[7] Deng-Chyang Wu,et al. Low Frequency of Opportunistic Infections in Patients Receiving Vedolizumab in Clinical Trials and Post-Marketing Setting , 2018, Inflammatory bowel diseases.
[8] L. Lix,et al. Incidence of Clostridium difficile Infection Among Individuals With Inflammatory Bowel Disease , 2017 .
[9] T. Bessissow,et al. Management of inflammatory bowel disease with Clostridium difficile infection , 2017, World journal of gastroenterology.
[10] C. Brensinger,et al. Increasing Incidence of Multiply Recurrent Clostridium difficile Infection in the United States , 2017, Annals of Internal Medicine.
[11] A. Shin,et al. Management of Clostridium difficile Infection in Inflammatory Bowel Disease: Expert Review from the Clinical Practice Updates Committee of the AGA Institute , 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[12] A. Petersen,et al. Inflammatory Bowel Disease Patients Are at Increased Risk of Invasive Pneumococcal Disease: A Nationwide Danish Cohort Study 1977–2013 , 2015, The American Journal of Gastroenterology.
[13] G. Faich,et al. Occurrence of adverse events among patients with inflammatory bowel disease in the HealthCore Integrated Research Database , 2015, Current medical research and opinion.
[14] A. Seicean,et al. Ulcerative colitis worsened after Clostridium difficile infection: efficacy of infliximab. , 2014, World journal of gastroenterology.
[15] W. Sandborn,et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. , 2012, The New England journal of medicine.
[16] A. Ananthakrishnan,et al. Temporal trends in disease outcomes related to Clostridium difficile infection in patients with inflammatory bowel disease , 2011, Inflammatory bowel diseases.
[17] D. Rampton,et al. Systematic review: Clostridium difficile and inflammatory bowel disease , 2011, Alimentary pharmacology & therapeutics.
[18] A. Ananthakrishnan,et al. Impact of Clostridium difficile on inflammatory bowel disease , 2010, Expert review of gastroenterology & hepatology.
[19] S. Schneeweiss,et al. Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections , 2009, Alimentary pharmacology & therapeutics.
[20] H. Tilg,et al. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. , 2009, Journal of Crohn's & colitis.
[21] G. Kaplan,et al. A National Survey of the Prevalence and Impact of Clostridium difficile Infection Among Hospitalized Inflammatory Bowel Disease Patients , 2008, The American Journal of Gastroenterology.
[22] Kimberly A. Reske,et al. Incidence of Clostridium difficile infection in inflammatory bowel disease. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[23] R. Pounder,et al. Clostridium difficile and inflammatory bowel disease. , 1983, Gut.
[24] W. Sandborn,et al. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. , 2017, The New England journal of medicine.